Silodosin

ATC Code G04CA04

Silodosin

Definition

An orally available, alpha-1 adrenoreceptor (alpha-1a) selective antagonist that can be used to relieve symptoms of benign prostate hyperplasia (BPH). Upon administration, silodosin selectively binds alpha-1a receptors located in the human prostate and bladder with high affinity and blocks signaling pathways mediated by alpha-1a. Blockade of these receptors causes smooth muscle relaxation, lowers intraurethral pressure, and results in improved urine flow and a reduction in the symptoms of BPH, such as difficulty with urinating, painful urination, urinary frequency and incomplete bladder emptying. In addition, silodosin may be used to improve lower urinary tract symptoms, which can occur after receiving radiation therapy for prostate cancer.

Also known as Rapaflo, Rapilif, SILODOSIN, Silodyx, Urief, Urorec — per NCIT

Also identified as

Indications

Disease Relation Source
Benign prostatic hyperplasia may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Genitourinary system may treat a disease of this organ DERIVED · CC BY 4.0
Male reproductive system may treat a disease of this organ DERIVED · CC BY 4.0
Prostate may treat a disease of this organ DERIVED · CC BY 4.0
Reproductive system may treat a disease of this organ DERIVED · CC BY 4.0

4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.